Current Oncology Clinical Trials
More people are surviving cancer thanks to research gained through cancer clinical trials. With the collective help of doctors, researchers and cancer patients who choose to participate, cancer clinical trials are able to test the value of the latest research findings of the
UNC Rex Cancer Care participates in ongoing cancer clinical trials in collaboration with the University of North Carolina-Chapel Hill. These trials can take several years to complete. They are required by law to include a protocol or action plan for each patient as well as informed consent. In return, knowledge gained from these trials has led to increased survival for many cancers including Hodgkin's disease, certain leukemias, breast, uterine, testicular and bladder cancers.
Cancer knows no boundaries. It touches everyone, whether through personal diagnosis or knowledge of someone with cancer. The statistics are alarming, but the good news is that dramatic improvements have been made in the diagnosis and treatment of cancer as a direct result of invaluable research of cancer clinical trials. The trials open currently at UNC Rex Cancer Care include the following:
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy - (also open at the Rex Cancer Center of Wakefield)
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (six cycles of Docetaxel plus Cyclophosphamide or four cycles of Doxorubicin plus Cyclophosphamide followed by weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-positive or High-risk Node-negative HER2 Low Invasive Breast Cancer - (also open at the Rex Cancer Center of Wakefield)
SWOG 1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. (RxPONDER) (also open at the Rex Cancer Center of Wakefield)
SWOG 1207: A Phase III Randomized, Placebo-controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and Her2Neu Negative Breast Cancer (also open at the Rex Cancer Center of Wakefield)
A211201: change in mammographic density with metformin use: a companion study to NCIC study MA.32.
ATEMPT- A randomized Phase II study of adjuvant trastuzumab emtansine (T-DM1) vs. Paclitaxel in combination with Trastuzumab for Stage I HER2-positive Breast Cancer
RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2+ Esophageal Adenocarcinoma
LCCC 1029: Randomized Placebo-Controlled Phase II Study of Regorafenib in Combination with FOLFIRI versus Placebo & FOLFIRI as 2nd Line Treatment in Patients with Metastatic Colorectal Cancer
CALGB 80702: Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (also open at the Rex Cancer Center of Wakefield)
LCCC 1315: Phase Ib/II study of neoadjuvant chemoradiotherapy with CRLX-101 and capecitabine for locally advanced rectal cancer (also open at the Rex Cancer Center of Wakefield)
S1001: A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma.
CC-5013-NHL-008: The MAGNIFY Study – Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
LCCC 1115: A Pilot Feasibility Trial of Induction Chemotherapy with ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)
C25003: A Randomized, Open Label, Phase III Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma (HL)
Chronic Phase CML (Chronic Myeloid Leukemia)
CAMN107AUS12T: Pilot Study to Assess Telemonitoring of Gleevec® (imatinib mesylate) or Tasigna® (nilotinib) Therapy - (also open at the Rex Cancer Center of Wakefield)
ECOG 2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response to Treatment with Lenalidomide Alone and in Combination with Epoetin Alfa in Subjects with Low or Intermediate-1 Risk MDS and Asymptomatic Anemia (also open at the Rex Cancer Center of Wakefield)
RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
RTOG 0815: A Phase III Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
RTOG 0924: A Phase III Randomized Trial of Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer
LCCC 1218: A Multi-Center Study to Evaluate Cardiovascular Risk Factors & Receipt of Primary & Preventive care in Prostate Cancer Patients who receive Definitive Radiation Therapy & Androgen Deprivation Therapy
LCCC 0916: Carolina Senior: UNC Registry for Older Patients - (also open at the Rex Cancer Center of Wakefield)
LCCC 0824: Tissue Procurement for Hematolymphoid Conditions
LCCC 1325: Improving Survivorship Care through Enhanced Communication and Coordination: A Pilot Study (also open at the Rex Cancer Center of Wakefield)
LCCC 1210: A Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly nab-Paclitaxel as Second Line Treatment for Elderly Patients with advanced Lung Cancer
ECOG 5508: A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab & Pemetrexed following Carboplatin, Paclitaxel & Bevacizumab for Advanced Non-Squamous Non Small Cell Lung Cancer (NSCLC) (also open at the Rex Cancer Center of Wakefield)
Cancer clinical trials available today are early detection/screening trials, diagnostic trials, quality-of-life/supportive care trials, treatment trials and prevention trials.
For more information about clinical trials open at Rex Cancer Center, call our oncology research manager, Nancy Burns, at (919) 784-7209.